2020
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
Ang Y, Ho G, Soo R, Sundar R, Tan S, Yong W, Ow S, Lim J, Chong W, Soe P, Tai B, Wang L, Goh B, Lee S. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer 2020, 20: 1118. PMID: 33203399, PMCID: PMC7672922, DOI: 10.1186/s12885-020-07616-4.Peer-Reviewed Original ResearchConceptsProgression-free-survivalAdvanced solid tumorsBreast cancer patientsSolid tumorsCancer patientsMedian progression-free-survivalRandomized phase II trialMetastatic breast cancer patientsClinical-benefit rateProphylactic G-CSFNon-haematological toxicityPrimary tumor siteAdministration of sunitinibPhase II trialAdvanced solid cancersMedian OSHaematological toxicityDoxorubicin-cyclophosphamideTrial registrationThe studyII trialNeutrophil nadirPrimary endpointSecondary endpointsG-CSFIntermittent administration
2017
Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors
Sundar R, Miranda S, Carreira S, Chénard-Poirier M, Rodrigues D, Figueiredo I, Bertan C, Yuan W, Perez D, Ferreira A, Tunariu N, Mateo J, Bono J. Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. Cancer Research 2017, 77: 3807-3807. DOI: 10.1158/1538-7445.am2017-3807.Peer-Reviewed Original ResearchATM protein lossAdvanced solid tumorsPlatinum chemotherapyPlatinum therapyATM lossClinical outcomesMetastatic sitesATM mutationsIHC lossSolid tumorsNext generation sequencingAmerican Association for Cancer Research annual meetingsSensitivity to platinum therapySomatic ATM mutationsAdvanced solid cancersSites of patientsNuclear staining intensityRabbit monoclonal antibodyLoss of ATM expressionProtein lossColorectal cancer cohortDNA damage repair signalingTP53 mutationsArchival tumorsH-score
2015
127O Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results
Heong V, Koe P, Yong W, Soo R, Chee C, Thian Y, Gopinathan A, Wong A, Sundar R, Ho J, Friedlander S, McCauley D, Choe-Juliak C, Lee S, Goh B, Tan D. 127O Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results. Annals Of Oncology 2015, 26: ix37. DOI: 10.1093/annonc/mdv521.03.Peer-Reviewed Original Research